Takeda Pharmaceutical has partnered with Resolve Therapeutics, a spin-out from the University of Washington, to develop novel compounds for the treatment of systemic lupus erythematosus and other autoimmune diseases, including the company’s lead programme RSLV-132. Resolve will be responsible for the first Phase Ib/IIa trial of RSLV-132 in lupus patients, on completion of which Takeda will have the exclusive option to license the compound and all other compounds from Resolve’s platform. If exercised, the option will provide an exit for the investors of Resolve.